Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …

Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced
pluripotent stem cells (iPSCs) is an attractive approach for" off-the-shelf" CAR T cell …

In chronic infections and cancer, T cells are exposed to persistent antigen and/or
inflammatory signals. This scenario is often associated with the deterioration of T cell …

Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have
facilitated further development of T-cell immunotherapy against wide variety of diseases …

The discovery of somatic cell nuclear transfer proved that somatic cells can carry the same
genetic code as the zygote, and that activating parts of this code are sufficient to reprogram …

Human induced pluripotent stem cells (iPSCs) provide a potentially unlimited resource for
cell therapies, but the derivation of mature cell types remains challenging. The histone …

Avoiding the immune rejection of transplanted T cells is central to the success of allogeneic
cancer immunotherapies. One solution to protecting T-cell grafts from immune rejection …

Age-associated neurological diseases represent a profound challenge in biomedical
research as we are still struggling to understand the interface between the aging process …

Adoptive transfer of receptor-engineered T cells has produced impressive results in treating
patients with B cell leukemias and lymphomas. This success has captured public …